Please assess the completion status of the following clinical trial:

Trial Title: Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are scheduled to undergo surgery within 10 days for fracture of inner or outer femoral neck (trochanteric and subtrochanteric)~Exclusion Criteria:~* Subjects with risks of hemorrhage~* Subjects with thrombolic risks~* Subjects who weigh less than 40 kg~* Subjects who are pregnant or suspect pregnancy, or subjects who want to become pregnant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DU-176b (Type: EXPERIMENTAL): DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery
- Enoxaparin sodium (Type: ACTIVE_COMPARATOR): Enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).